ICH E6(R3) vs ICH E8(R1): How They Work Together

How ICH E6(R3) and E8(R1) work together to support quality-by-design, risk-based oversight, and improved patient protection in clinical trials.

ICH E6(R3) vs ICH E8(R1): How They Work Together

How ICH E6(R3) and E8(R1) work together to support quality-by-design, risk-based oversight, and improved patient protection in clinical trials.
Cyntegrity logo – Risk-Based Quality Management Solutions

Complementary Guidance for Modern Clinical Trials

ICH E6(R3) and E8(R1) are often discussed separately but in practice, they reinforce each other.

Together, they shift clinical research from checklist execution to purposeful design and proactive oversight.

Where E8(R1) focuses on how to design meaningful and patient-relevant studies, E6(R3) focuses on how to conduct those studies with transparency, quality, and documented oversight.

How Their Focus Areas Align​

Area

E8(R1) Focus

E6(R3) Focus

Practical Effect

Trial Design

Ensuring study objectives are meaningful and feasible

Embedding quality and CtQ factors from the start

More realistic endpoints & fewer amendments

Quality by Design (QbD)

Encourages thoughtful planning

AEs with severity and timing context

Quality is planned, not patched

Risk-Based Approach

Encourages risk thinking in protocol development

Defines system- and trial-level RBQM processes

Monitoring becomes focused and timely

Practical Protection

Balances burden vs. value

Uses broader risk terminology (harm/hazard)

Stronger alignment with ethical safety decision-making

Documentation & Traceability

Clarifies why data collection matters

Requires documented oversight and rationale

Inspection readiness improves naturally

Trial Design

E8(R1) Focus​

Ensuring study objectives are meaningful and feasible

E6(R3) Focus​

Embedding quality and CtQ factors from the start

Practical Effect

More realistic endpoints & fewer amendments

Quality by Design (QbD

E8(R1) Focus​

Encourages thoughtful planning

E6(R3) Focus​

AEs with severity and timing context

Practical Effect

Quality is planned, not patched

Risk-Based Approach

E8(R1) Focus​

Encourages risk thinking in protocol development

E6(R3) Focus​

Defines system- and trial-level RBQM processes

Practical Effect

Monitoring becomes focused and timely

Practical Protection

E8(R1) Focus​

Balances burden vs. value

E6(R3) Focus​

Uses broader risk terminology (harm/hazard)

Practical Effect

Stronger alignment with ethical safety decision-making

Documentation & Traceability

E8(R1) Focus​

Clarifies why data collection matters

E6(R3) Focus​

Requires documented oversight and rationale

Practical Effect

Inspection readiness improves naturally

Why This Matters Now

Trials are more complex, timelines are tighter, and patient populations are more specific.

 

Both guidelines push organizations to:

  • Spend time on what influences outcomes
  • Monitor what carries real risk
  • Document why decisions are made

 

This results in fewer surprises, smoother execution, and clearer inspection narratives.

Bottom Line

You don’t “choose” E6(R3) or E8(R1). You use E8(R1) to design the study and use E6(R3) to run it responsibly.


Organizations that align study design (E8) with operational oversight (E6) create trials that are:

  • safer,
  • more predictable, 
  • more efficient,
  • and easier to defend to regulators.

E6(R3) & E8(R1) Comparison Presentation

If you are using the MyRBQM® Portal, CtQ factors, risk reviews, and monitoring decisions can be linked directly to study documentation — supporting inspection-ready traceability.

Stay Informed with Us

Risk-based quality management in 2026

Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials....
Diagram illustrating the FDA Total Product Lifecycle (TPLC) management approach for AI and machine learning devices, showing a continuous cycle of design, validation, submission, monitoring, and update.

FDA AI Guidance 2025 Interactive Visualizer

Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios....

Media Inquiries

Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.

ICH E6(R3) vs E8(R1)

ICH E6(R3) vs E8(R1)

▶ Watch the conversation